Updated Results of Phase II Study GPI-006-02 of Single-Agent Romidepsin in Relapsed/Refractory PTCL


Updated Results of Phase II Study GPI-006-02 of Single-Agent Romidepsin in Relapsed/Refractory PTCL
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Steven M Horwitz, MD (3/14/13)

Coiffier B et al. Romidepsin induces durable responses in patients with peripheral T-cell lymphoma: GPI-06-0002 study update. Proc ASH 2012;Abstract 3641.

Dr Horwitz is Assistant Attending in the Division of Hematologic Oncology’s Lymphoma Service at Memorial Sloan-Kettering Cancer Center in New York, New York.